Employees: 304
Size Jenkem Technology (688356.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $563M, the 3405th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥63.45 on 18 Nov 2026.
Performance Over six months the shares fell 29.5%, against -21.2% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 51.6% over the last twelve months (peer median +1.8%); the operating margin is 11.5% (peer median 5.1%).
Valuation It trades at 30.2× forward earnings against a peer median of 11.3× (3rd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.5 points below its cost of capital (14.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥375M | CN¥313M | CN¥222M | CN¥287M | CN¥403M |
| Revenue growth | — | +41% | -23% | -29% | — |
| Gross profit | CN¥282M | CN¥182M | CN¥135M | CN¥217M | CN¥330M |
| EBITDA | n/a | CN¥104M | CN¥64.5M | CN¥152M | CN¥214M |
| Net income | CN¥50.5M | CN¥61.7M | CN¥29.8M | CN¥116M | CN¥187M |
| Free cash flow | CN¥117M | CN¥30.2M | CN¥99.9M | CN¥49.3M | -CN¥16.1M |
| Capital expenditure | CN¥81.8M | CN¥55.8M | CN¥28.3M | CN¥83.7M | CN¥213M |
| Total debt | CN¥5.56M | CN¥7.12M | CN¥13.6M | CN¥8.81M | CN¥4.64M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688356.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.8% | -11.4% | 4th lowest of 21 |
| 6-month return | -29.5% | -21.2% | 7th lowest of 21 |
| Distance from 52-week high | -54.3% | -42.9% | 5th lowest of 21 |
| Revenue growth (TTM) | +51.6% | +1.8% | 2nd highest of 19 |
| Operating margin | 11.5% | 5.1% | 5th highest of 18 |
| Forward P/E | 30.2× | 11.3× | 3rd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 36.4% | -4.0% | 2nd most demanding of 9 |
| Growth delivered (Del g) | +11.2% | +10.4% | 4th highest of 9 |
| Hurdle (Req g minus delivered) | +25.2 pp | -12.8 pp | 2nd most demanding of 9 |
| ROIC minus cost of capital | -7.5 pp | -3.6 pp | 6th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |